Clinical trials: Adult Attention Deficit Hyperactivity Disorder
- Condition Adult Attention Deficit Hyperactivity Disorder
- Funder type Industry (pharma, biotech, devices)
Attention Deficit Disorder With Hyperactivity
A Trial to Characterize Differences in Blood Levels of Different Lots of Centanafadine QD XR and to Understand the Effect of Food on Blood Levels
The purpose of this study is to evaluate the dose strength equivalence of to-be-marketed (TBM) centanafadine (CTN) once daily (QD) extended release (XR) when administered as 2 capsules of 164.4 milligrams (mg) or as a single…
- Trial name
- NCT07253441
- Testing
- CTN XR (TBM), CTN SR, CTN XR (Clin)
- Where
- 2 sites in United States
- Volunteers
- 174 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Attention Deficit-Hyperactivity Disorder
Real World Evidence of the Efficacy and Safety of FOQUEST
This study is a four-month, phase IV, open-label study of ADHD symptomatology and functional outcomes in pediatric (6 to 17 years old) and adult (≥18 years or older) patients with ADHD treated with FOQUEST or VYVANSE.
- Trial name
- reFOQus (NCT04152629)
- Testing
- Methylphenidate Hydrochloride, Lisdexamfetamine Dimesylate
- Where
- 12 sites in Canada
- Volunteers
- 257 people
- Sponsor
- Purdue Pharma, Canada
Attention Deficit Hyperactivity Disorder
Software Treatment for Actively Reducing Severity of ADHD in Adults (STARS ADHD Adult)
The purpose of this study is to evaluate the effects of the videogame-like digital therapy on attentional functioning and symptoms in Adults diagnosed with ADHD.
- Trial name
- NCT05183919
- Testing
- Digital Treatment
- Where
- 14 sites in United States
- Volunteers
- 223 people
- Sponsor
- Akili Interactive Labs, Inc.
Attention Deficit Hyperactivity Disorder
A Long Term Follow-Up Study for Asian Adult Patients With Attention Deficit Hyperactivity Disorder
The purpose of this study is to assess long-term safety and tolerability in adult patients who have completed a previous atomoxetine study.
- Trial name
- NCT00969618
- Testing
- Atomoxetine
- Where
- 12 sites in Japan
- Volunteers
- 211 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Hyperactivity Disorder, Attention Deficit Disorders With Hyperactivity
An Open-label Study of NRP104 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
The purpose of this study is to assess the long-term safety and efficacy of three NRP104 doses of 30 mg, 50 mg, or 70 mg, administered at the same time daily, in the treatment of adults with ADHD.
- Conditions
- Attention Deficit Hyperactivity Disorder, Attention Deficit Disorders With Hyperactivity, Attention Deficit Hyperactivity Disorders
- Trial name
- NCT00337285
- Testing
- Vyvanse (lisdexamfetamine dimesylate), NRP104
- Where
- 45 sites in United States
- Volunteers
- 349 people
- Sponsor
- New River Pharmaceuticals
Attention Deficit Hyperactivity Disorder
A Bioequivalence (BE) Study in Healthy Subjects
To demonstrate the bioequivalence of 12.5 milliliters (mL) of atomoxetine oral solution (4 milligrams per milliliter [mg/mL]) compared with 2 capsules of atomoxetine (25 mg per capsule) in healthy adult male Japanese subjects.
- Trial name
- NCT01177943
- Testing
- Atomoxetine
- Where
- Japan
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Attention Deficit Hyperactivity Disorder
Quality Assurance of Administering Methylphenidate in Adults With Attention Deficit Hyperactivity Disorder (ADHD) - QUMEA
Investigation of efficacy of high-dose extended-release Methylphenidate in adults with ADHD, compared with a placebo
- Trial name
- QUMEA (NCT00730249)
- Testing
- methylphenidate hydrochloride
- Where
- 11 sites in Germany
- Volunteers
- 150 people
- Sponsor
- Medice Arzneimittel Pütter GmbH & Co KG
Impulsive Aggression Comorbid With ADHD
Phase I Study to Assess the Absorption, Metabolism, and Excretion of [14C] Labeled SPN-810M
An Open-Label, Single-Dose, Mass-Balance Study to Assess the Absorption, Metabolism, and Excretion of Radio Labeled SPN-810M in Healthy Adult Male Volunteers
- Trial name
- NCT02023606
- Testing
- SPN-810M
- Where
- United Kingdom
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Supernus Pharmaceuticals, Inc.
Attention Deficit Disorder With Hyperactivity
Safety and Efficacy of SPD465 in Adults With ADHD
The purpose of the study is to evaluate how safe and how well SPD465 works compared to placebo in adults with ADHD. It is hypothesized that SPD465 will achieve an extended duration of clinical benefit.
- Trial name
- NCT00202605
- Testing
- Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulfate, USP, d-amphetamine saccharate, d,I-amphetamine aspartate monohydrate
- Where
- 4 sites in United States
- Volunteers
- 72 people
- Sponsor
- Shire
Attention Deficit Disorder With Hyperactivity
Mazindol Controlled Release in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
The purpose of this study is to determine whether a controlled release formulation of mazindol is more effective than a placebo in the treatment of Attention Hyperactivity Disorder (ADHD) in adults.
- Trial name
- NCT02808104
- Testing
- mazindol
- Where
- 7 sites in United States
- Volunteers
- 84 people
- Sponsor
- NLS Pharmaceutics
Attention Deficit Disorder With Hyperactivity
Safety of SPD465 in Treating Adults With ADHD.
The purpose of this study is to assess the safety and effectiveness of SPD465 in the treatment of ADHD. The study will also look at how SPD465 affects sleep.
- Trial name
- NCT00152035
- Testing
- Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulfate, USP, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate.
- Volunteers
- 505 people
- Sponsor
- Shire
Attention-Deficit/Hyperactivity Disorder
Open-label Long-Term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD
Open label, flexible dose, long-term multicenter study of safety and efficacy of SPN-812 in adult ADHD patients
- Trial name
- NCT04143217
- Testing
- SPN-812
- Where
- 38 sites in United States
- Volunteers
- 159 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Attention Deficit Disorder With Hyperactivity, Amphetamine-Related Disorders
Safety, Tolerability and Abuse Liability Study of Intravenous NRP104 in Adults With Stimulant Abuse Histories
This research is being done to evaluate if NRP 104 is a safe drug. The other purpose is to learn if NRP104, when injected into a vein, produces a high and any other effects like amphetamine and other stimulant drugs that are…
- Conditions
- Attention Deficit Disorder With Hyperactivity, Amphetamine-Related Disorders, Substance-Related Disorders
- Trial name
- NCT00247572
- Testing
- NRP104
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- New River Pharmaceuticals
ADHD
Adult Normative Performance of the Quotient ADHD System
This study is being conducted to enhance and extend the clinical utility of the Quotient® ADHD System Adolescent and Adult Version Test by adding large numbers of well-screened controls to the existing Quotient® ADHD System…
- Trial name
- ADHD (NCT01308450)
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- BioBehavioral Diagnostics Company
Attention-Deficit/Hyperactivity Disorder (ADHD)
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD
This study will evaluate the efficacy and safety of SPN-812 (Viloxazine extended-release capsules; 200-600 mg) in adults 18-65 years of age with Attention-Deficit/Hyperactivity Disorder (ADHD).
- Trial name
- NCT04016779
- Testing
- SPN-812
- Where
- 37 sites in United States
- Volunteers
- 374 people
- Sponsor
- Supernus Pharmaceuticals, Inc.